Yeast-based cannabinoids Demetrix is actively developing yeast-based production methods for cannabinoids, presenting a potential selling point for supply chain partners and manufacturers seeking scalable, biotech-driven cannabinoid supply.

Beauty and personal care A multi-year supply agreement with Evonik to expand cannabinoid bioactives in beauty and personal care signals strong traction in the cosmetic vertical and suggests opportunities to cross-sell additional bioactives or expanded ingredient portfolios.

Rare cannabinoid focus Demetrix has launched programs around rare cannabinoids such as cannabigerol (CBG), indicating an aptitude for niche ingredients that can differentiate products in health, wellness, and skincare segments.

Strategic partnerships Early-stage and growth funding from notable investors along with research collaborations imply a readiness to engage in co-development, licensing, or pilot-scale collaborations with pharma, biotech, or CPG firms.

Berkeley roots, biotech footprint Geographic base in Berkeley with additional offices and a biotech-focused profile suggests opportunities for regional collaborations, contract development, and joint ventures with nearby universities, research institutes, and regional manufacturers.